Sam Brusco, Associate Editor02.27.24
Know Labs has unveiled its KnowU wearable, non-invasive continuous glucose monitor (CGM). The company had announced its first prototype in summer 2023.
KnowU features the sensor the company intends to submit to the U.S. Food and Drug Administration (FDA) for clearance. The company said it’s been tested and proven stable and accurate in the lab setting. It was included in the prototype to validate stability outside the lab, and is now smaller and wearable.
The device can be worn with an adhesive so the wearer can clip the sensor on or off, or on the wrist or forearm with a strap. It includes onboard computing power and built-in machine learning capabilities, as well.
KnowU will support accelerated collection of data, including determining the tech’s performance throughout continuous wear, on different body locations, and within more expansive glycemic ranges and diverse populations.
The proprietary radiofrequency (RF) sensor measures glucose levels with dielectric spectroscopy by quickly scanning a range of RF frequencies. It records voltage values detected at each frequency to quantify—using machine learning algorithms—real-time, continuous blood glucose levels.
Know U leverages glucose’s dielectric properties, including its ability to store electrical energy in an electrical field, as measured though a voltage reading received after broadcasting each frequency. The company aims to deploy it in large-scale, external clinical trials during 2024.
“The prevalence of diabetes is growing globally at an alarming rate. Millions of people face significant barriers in accessing the technology and treatment they need to effectively manage their diabetes,” said Ron Erickson, CEO and chairman at Know Labs. “Know Labs is committed to delivering an accessible, affordable, and accurate solution that improves the current standard of care and enhances the quality of life for those living with diabetes. The KnowU brings us closer to a future where equitable care in diabetes management will become a reality.”
KnowU features the sensor the company intends to submit to the U.S. Food and Drug Administration (FDA) for clearance. The company said it’s been tested and proven stable and accurate in the lab setting. It was included in the prototype to validate stability outside the lab, and is now smaller and wearable.
The device can be worn with an adhesive so the wearer can clip the sensor on or off, or on the wrist or forearm with a strap. It includes onboard computing power and built-in machine learning capabilities, as well.
KnowU will support accelerated collection of data, including determining the tech’s performance throughout continuous wear, on different body locations, and within more expansive glycemic ranges and diverse populations.
The proprietary radiofrequency (RF) sensor measures glucose levels with dielectric spectroscopy by quickly scanning a range of RF frequencies. It records voltage values detected at each frequency to quantify—using machine learning algorithms—real-time, continuous blood glucose levels.
Know U leverages glucose’s dielectric properties, including its ability to store electrical energy in an electrical field, as measured though a voltage reading received after broadcasting each frequency. The company aims to deploy it in large-scale, external clinical trials during 2024.
“The prevalence of diabetes is growing globally at an alarming rate. Millions of people face significant barriers in accessing the technology and treatment they need to effectively manage their diabetes,” said Ron Erickson, CEO and chairman at Know Labs. “Know Labs is committed to delivering an accessible, affordable, and accurate solution that improves the current standard of care and enhances the quality of life for those living with diabetes. The KnowU brings us closer to a future where equitable care in diabetes management will become a reality.”